Conference Proceedings
Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK plus NSCLC
J Mazieres, L Iadeluca, A Shaw, B Solomon, T Bauer, F De Marinis, E Felip, Y Goto, D Kim, T Mok, A Reisman, H Thurm, A Polli, G Liu
JOURNAL OF THORACIC ONCOLOGY | ELSEVIER SCIENCE INC | Published : 2021